Literature DB >> 15731925

Leiomyosarcoma and malignant fibrous histiocytoma share similar allelic imbalance pattern at 9p.

Muna Sabah1, Robert Cummins, Mary Leader, Elaine Kay.   

Abstract

Formalin-fixed, paraffin-embedded tissue from 45 soft tissue sarcomas was analysed for allelic imbalance/loss of heterozygosity (AI/LOH) of chromosome 9. The specimens consisted of 17 cases of soft tissue leiomyosarcoma (LMS), 4 cases of cutaneous LMS, 22 cases of conventional malignant fibrous histiocytoma (MFH) and 2 cases of angiomatoid fibrous histiocytoma. All cases were categorised morphologically and immunohistochemically. DNA was microdissected from normal and neoplastic tissues. AI/LOH was performed using six microsatellite markers on the 9p region. The frequency of allelic imbalance at different loci on chromosome 9p was analysed in LMS and MFH and then compared with values previously examined in synovial sarcoma and malignant peripheral nerve sheath tumour. Although AI/LOH and microsatellite instability (MSI) were more frequent in MFH, LMS and MFH groups showed similar patterns of allelic imbalance at the 9p region. Alterations of chromosome 9p have been reported in many cell lines and tumours including LMS and MFH. 9p21 region encodes p16(INK4A) and p15(INK4B). Allelic imbalance observed at 9p 21 in this study suggests that alterations of the negative cell cycle regulators may be an important step in the pathogenesis of MFH and LMS. However, the most frequent allelic imbalance was observed at 9p24 at D9S230. Alterations of this locus were very rare in synovial sarcoma and malignant peripheral nerve sheath tumours and were absent in cutaneous LMS and angiomatoid fibrous histiocytoma. This locus may point to the existence of a genetically altered tumour suppressor gene involved in the pathogenesis of LMS and MFH. Our results support the hypothesis that MFHs may represent a morphological pathway in tumour progression of LMSs.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15731925     DOI: 10.1007/s00428-004-1190-2

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  25 in total

1.  Leiomyosarcomas and most malignant fibrous histiocytomas share very similar comparative genomic hybridization imbalances: an analysis of a series of 27 leiomyosarcomas.

Authors:  J Derré; R Lagacé; A Nicolas; A Mairal; F Chibon; J M Coindre; P Terrier; X Sastre; A Aurias
Journal:  Lab Invest       Date:  2001-02       Impact factor: 5.662

2.  Malignant giant cell tumor of soft parts. An analysis of 32 cases.

Authors:  J G Guccion; F M Enzinger
Journal:  Cancer       Date:  1972-06       Impact factor: 6.860

3.  Malignant fibrous histiocytoma. Nonspecific morphologic pattern, specific pathologic entity, or both?

Authors:  L P Dehner
Journal:  Arch Pathol Lab Med       Date:  1988-03       Impact factor: 5.534

4.  Angiomatoid "malignant" fibrous histiocytoma: a clinicopathologic study of 158 cases and further exploration of the myoid phenotype.

Authors:  J C Fanburg-Smith; M Miettinen
Journal:  Hum Pathol       Date:  1999-11       Impact factor: 3.466

5.  A comprehensive genetic map of the human genome based on 5,264 microsatellites.

Authors:  C Dib; S Fauré; C Fizames; D Samson; N Drouot; A Vignal; P Millasseau; S Marc; J Hazan; E Seboun; M Lathrop; G Gyapay; J Morissette; J Weissenbach
Journal:  Nature       Date:  1996-03-14       Impact factor: 49.962

6.  Malignant fibrous histiocytoma phenotype in pleomorphic sarcoma differentiation in recurrent disease.

Authors:  M J Costa
Journal:  Arch Pathol Lab Med       Date:  1994-02       Impact factor: 5.534

Review 7.  Malignant fibrous histiocytoma: morphologic pattern or pathologic entity?

Authors:  K Hollowood; C D Fletcher
Journal:  Semin Diagn Pathol       Date:  1995-08       Impact factor: 3.464

8.  Loss of heterozygosity of chromosome 9p and loss of p16INK4A expression are associated with malignant gastrointestinal stromal tumors.

Authors:  Muna Sabah; Robert Cummins; Mary Leader; Elaine Kay
Journal:  Mod Pathol       Date:  2004-11       Impact factor: 7.842

9.  Pleomorphic malignant fibrous histiocytoma: fact or fiction? A critical reappraisal based on 159 tumors diagnosed as pleomorphic sarcoma.

Authors:  C D Fletcher
Journal:  Am J Surg Pathol       Date:  1992-03       Impact factor: 6.394

10.  Molecular classification of synovial sarcomas, leiomyosarcomas and malignant fibrous histiocytomas by gene expression profiling.

Authors:  Y-F Lee; M John; S Edwards; J Clark; P Flohr; K Maillard; M Edema; L Baker; D C Mangham; R Grimer; R Wooster; J M Thomas; C Fisher; I Judson; C S Cooper
Journal:  Br J Cancer       Date:  2003-02-24       Impact factor: 7.640

View more
  5 in total

1.  Loss of p16INK4A expression is associated with allelic imbalance/loss of heterozygosity of chromosome 9p21 in microdissected synovial sarcomas.

Authors:  Muna Sabah; Robert Cummins; Mary Leader; Elaine Kay
Journal:  Virchows Arch       Date:  2005-08-05       Impact factor: 4.064

2.  Two novel BRM insertion promoter sequence variants are associated with loss of BRM expression and lung cancer risk.

Authors:  G Liu; S Gramling; D Munoz; D Cheng; A K Azad; M Mirshams; Z Chen; W Xu; H Roberts; F A Shepherd; M S Tsao; D Reisman
Journal:  Oncogene       Date:  2011-04-11       Impact factor: 9.867

3.  Primary and metastatic high-grade pleomorphic sarcoma/malignant fibrous histiocytoma of the gastrointestinal tract: an approach to the differential diagnosis in a series of five cases with emphasis on myofibroblastic differentiation.

Authors:  Abbas Agaimy; Andreas Gaumann; Josef Schroeder; Wolfgang Dietmaier; Arndt Hartmann; Ferdinand Hofstaedter; Peter H Wünsch; Thomas Mentzel
Journal:  Virchows Arch       Date:  2007-09-14       Impact factor: 4.064

4.  Atypical fibroxanthoma.

Authors:  Akio Sakamoto
Journal:  Clin Med Oncol       Date:  2008-02-09

5.  Genetic profiling differentiates second primary tumors from metastases in adult metachronous soft tissue sarcoma.

Authors:  Josefin Fernebro; Ana Carneiro; Anders Rydholm; Henryk A Domanski; Anna Karlsson; Ake Borg; Mef Nilbert
Journal:  Sarcoma       Date:  2009-02-02
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.